Secondary prevention of cardiovascular diseases: current state of the art

Area of Science:

• Cardiology
• Preventive Medicine
• Pharmacology

Background:

• Cardiac event prevention is risk-stratified, with >10% 10-year risk considered very high.
• Patients with coronary artery disease, diabetes, or severe hypertension face very high cardiac event risk.
• Primary and secondary prevention strategies often overlap, especially in managing multiple risk factors.

Purpose of the Study:

• To outline current and emerging strategies for preventing cardiac events.
• To highlight the importance of risk assessment in tailoring preventive interventions.
• To introduce novel therapeutic options for cardiovascular disease management.

Main Methods:

• Review of general recommendations including behavioral, nutritional, and physical activity modifications.
• Discussion of drug-based strategies targeting hypercholesterolemia, diabetes, hypertension, and platelet aggregation.
• Inclusion of cardiac rehabilitation programs post-hospitalization for heart failure or acute coronary syndrome.

Main Results:

• Established guidelines recommend lifestyle modifications and pharmacotherapy for cardiovascular risk reduction.
• Emerging treatments like PCSK9 inhibitors for hypercholesterolemia and SGLT2 inhibitors for diabetes show significant potential.
• These new agents offer promising avenues for reducing event rates in high-risk populations.

Conclusions:

• A multifaceted approach combining lifestyle interventions, risk factor management, and novel pharmacotherapies is crucial for cardiac event prevention.
• PCSK9 and SGLT2 inhibitors represent significant advancements in managing hypercholesterolemia and diabetes-related cardiovascular risk.
• Personalized risk assessment and updated treatment strategies are essential for optimizing patient outcomes in cardiovascular medicine.